GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs Rybelsus ) 7 mg and 14 mg tablets to reduce the risk of major adverse cardiac events (MACE) in adults with T2DM and who are at high risk for these events, including cardiovascular death, non-fatal myocardial infarction or non-fatal stroke
This is usually negligible
Diabetes Obes Metab 22(12):24872492 Verma S, Bhatta M, Davies M, Deanfield JE, Garvey WT, Jensen C, et al (2023) Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
We may also collect anonymous, aggregated data for aggregated trend analysis, which can be controlled anytime in Privacy Settings
Eli Lilly has reported phase 3 data for orforglipron in its ATTAIN trial update, and AstraZeneca has advanced its candidate following midstage results reported in industry coverage
Q., Zheng, S